Skip to main content

Table 4 Efficacy and immune responses of experimental vector vaccines against Mycoplasma hyopneumoniae tested in pigs.

From: Perspectives for improvement of Mycoplasma hyopneumoniae vaccines in pigs

Antigen Vector Route Number of vaccinations Significant decrease of Humoral response CMI responsea Other/comments References
Lung lesions Clinical signs M. hyopneumoniae numbers Serum BALFb
NrdF (R2) S. Typhimurium aroA SL3261c Oral 2 Yes    No IgA Yes Higher ADGb; IgA only after challenge [94]
P97 (R1R2) E. rhusiopathiae strain YS-19c Intranasal 2 Yes   Yes No   Yes   [95]
P97 (R1R2) E. rhusiopathiae strain Koganei 65–0.15 Oral 3 Yes   No IgG IgA Yes IgG and IgA only after challenge [96]
P97 (R1R2) Adenovirus Intranasal 2 Yes   Yes IgG, IgA IgA, IgG (saliva) Yes higher ADG; serum inhibited M. hyopneumoniae growth; minor decrease of lung inflammation
Commercial vaccine: no anti-P97 antibodies, better protection
[97]
  1. aCMI responses were tested by stimulation of peripheral blood mononuclear cells (PBMCs) and calculating stimulation indexes.
  2. bBALF, bronchoalveolar lavage fluid; ADG, average daily gain.
  3. cS. Typhimurium: Salmonella Typhimurium; E. rhusiopathiae: Erysipelothrix rhusiopathiae.